{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:58:29Z","timestamp":1793303909172,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000399","name":"Multiple Sclerosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2025.09.013","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:46:16Z","timestamp":1758620776000},"page":"76.e1-76.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trial of Enasidenib Maintenance Post-Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2-Mutated Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-5041","authenticated-orcid":false,"given":"Amandeep","family":"Salhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Knobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr M. Al","family":"Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet S.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoozeh","family":"Sahebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod A.","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2025.09.013_bib0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"7274","key":"10.1016\/j.jtct.2025.09.013_bib0002","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.013_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-15-0362","article-title":"Molecular pathways: IDH2 mutations-co-opting cellular metabolism for malignant transformation","volume":"22","author":"Stein","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.013_bib0004","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.013_bib0005","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.013_bib0006","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.013_bib0007","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/ejh.12271","article-title":"IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation","volume":"92","author":"Yamaguchi","year":"2014","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.013_bib0008","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.013_bib0009","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.09.013_bib0010","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.26580","article-title":"Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin","volume":"118","author":"Ravandi","year":"2012","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jtct.2025.09.013_bib0011","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.013_bib0012","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.013_bib0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","article-title":"Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation","volume":"15","author":"Kunadt","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2025.09.013_bib0014","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.013_bib0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.013_bib0016","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.013_bib0017","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/j.clml.2019.04.007","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients carrying isocitrate dehydrogenase mutations","volume":"19","author":"Salhotra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.013_bib0018","doi-asserted-by":"crossref","first-page":"479.e1","DOI":"10.1016\/j.jtct.2021.02.028","article-title":"Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"27","author":"Chen","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.013_bib0019","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2017.06.003","article-title":"TP53 and IDH2 somatic mutations are associated with inferior overall survival after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome","volume":"17","author":"Kharfan-Dabaja","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.013_bib0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/hematology.2024000589","article-title":"Maintenance strategies for relapse prevention and treatment","volume":"2024","author":"Geramita","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.013_bib0021","first-page":"435","article-title":"Enasidenib: An oral IDH2 inhibitor for the treatment of acute myeloid leukemia","volume":"9","author":"Myers","year":"2018","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.013_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbmt.2019.09.017","volume":"26","author":"Salhotra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.013_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.013_bib0024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2025.09.013_bib0025","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.013_bib0026","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.013_bib0027","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.013_bib0028","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.jtct.2025.09.013_bib0029","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7980","key":"10.1016\/j.jtct.2025.09.013_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41586-023-06546-y","article-title":"Reductive carboxylation epigenetically instructs T cell differentiation","volume":"621","author":"Jaccard","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.013_bib0031","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.013_bib0032","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.013_bib0033","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.013_bib0034","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41409-019-0553-x","article-title":"Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia","volume":"55","author":"Aldoss","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501437X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501437X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:32:14Z","timestamp":1769131934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672501437X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S266663672501437X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial of Enasidenib Maintenance Post-Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2-Mutated Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}